Screener
Xeris Biopharma Holdings, Inc. XERS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
FAQ
- What is Xeris Biopharma Holdings, Inc.'s EPS (diluted)?
- Xeris Biopharma Holdings, Inc. (XERS) reported EPS (diluted) of -$0.18 in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s EPS (diluted) changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s EPS (diluted) decreased by 1700.0% year-over-year, from -$0.01 to -$0.18.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s EPS (diluted) has grown at a -100.0% compound annual growth rate (CAGR), from -$1.54 to $0.00.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Xeris Biopharma Holdings, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude